Case report · 10 Aug 2026
Conference abstractPublished 24 Sep 2018
Development and commercialization of oral peptide and protein therapeutics: Trends and perspectives
Biopharmaceutical & Drug Delivery Consulting LLC, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The oral route is the most preferred non-invasive route of drug administration due to increased patient compliance. However, advancing oral peptide and protein therapeutics from bench to clinic and commercialization has been a formidable task. Despite major investments and scientific advances in this area over the last three decades, there is no oral water-soluble and poorly permeable (BCS III) peptide/protein drug product on the market. Oral drug delivery approaches used alone and in combination in preclinical and clinical studies include, chemical modifications, intestinal permeability/ absorption enhancers, such as lipids, surfactants, and proprietary molecules, and lipidic and polymeric micro-/nanoparticles with and without targetable ligands directed towards M-cells/Peyer’s patches in the intestinal mucosa. Upon introductory remarks on the Biopharmaceutics Classification Scheme (BCS) as applied to peptide therapeutics and characteristics of an ideal oral formulation, advantages and limitations with peptide therapeutics and drug development needs will be presented during the first part of the talk. Then preformulation and formulation development aspects of oral peptides, assessment criteria and development considerations with various delivery technologies will be discussed, followed by lessons learned from preclinical and clinical studies. The last part of the talk will summarize accomplishments to date, address commercialization issues and conclude with future developments in this field.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Trials.
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Panayiotis P Constantinides”
